2:42 PM
 | 
Sep 12, 2017
 |  BC Extra  |  Clinical News

GSK preparing submissions for Nucala in COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will submit regulatory applications this year for Nucala mepolizumab (SB-240563) to treat eosinophilic chronic obstructive pulmonary disease after reporting mixed data from the Phase III METREX and METREO trials.

In METREX, 100 mg mepolizumab given every four weeks significantly reduced the mean annual rate of moderate and severe exacerbations compared to placebo, meeting the primary...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >